Literature DB >> 2060759

A method for studies of an El Tor-associated antigen of Vibrio cholerae O1.

A M Svennerholm1, G Johnson, C Yan.   

Abstract

A method for studying the biotype El Tor associated mannose-sensitive haemagglutinin (MSHA) of V. cholerae O1 has been developed. By using crude MSHA adsorbed to chicken erythrocytes as solid phase antigen in an enzyme-linked immunosorbent assay (ELISA), antisera against V. cholerae of the El Tor biotype reacted in high titre with the MSHA-coated cells, whereas antisera against vibrios of the classical biotype did not bind significantly, i.e. in higher titre than pre-immune sera. The binding of anti-MSHA serum, or a monoclonal antibody against MSHA, to the MSHA-coated erythrocytes could be efficiently inhibited by crude MSHA as well as by El Tor vibrios whereas neither V. cholerae lipopolysaccharide nor different strains of classical vibrios had any inhibitory effect. These results support the existence of an El Tor-associated immunogen. They also suggest a possibility of determining antibodies against different haemagglutinins in ELISA without having access to purified antigens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060759     DOI: 10.1016/0378-1097(91)90082-l

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  3 in total

1.  Immune response to the mannose-sensitive hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139.

Authors:  F Qadri; G Jonson; Y A Begum; C Wennerås; M J Albert; M A Salam; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili.

Authors:  J Osek; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

3.  Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera.

Authors:  J Osek; G Jonson; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.